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Background:  Pts with prosthetic valves manifest diffuse myocardial fibrosis. It is unknown if this adversely impacts outcomes after cardiac 
resynchronization (CRT), as with infarction-related fibrosis.
Methods:  We included all pts (n=374) receiving CRT for standard indications with no significant coronary artery disease and identified those with 
a single prosthetic left-sided valve replaced ≥3 months prior to CRT. Pts underwent echo prior to and ≥6 months after CRT. Endpoints included death, 
cardiac transplant, or ventricular assist device (VAD).
Results:  The overall cohort was 62% male, aged 63 ± 13 y, 30% diabetic, and had QRS 173 ± 31 ms and LVEF 22 ± 7%. There were 39 prosthetic 
valve recipients (V); 27 were aortic and 12 were mitral. Pts without a prosthetic valve (NV) had less atrial fibrillation (AF) and were more frequently 
taking `-blockers than V pts but were otherwise similar (Table). While LVEF change did not differ significantly, NV pts manifested larger decreases 
in LVESD and LVEDD (p=0.03). Over 43 ± 22 mos, 116 (31%) pts died, received a transplant, or required VAD. V pts had shorter event-free survival, 
both on Cox univariate (HR 0.57, 0.34-0.97, p=0.04) and multivariate analysis (HR 0.46, 0.26-0.83, p=0.01), correcting for age, gender, diabetes, AF, 
QRS duration,`-blocker and ACE-I/ARB use, NYHA class 4 prevalence, and renal function.
Conclusions:  Pts with single prosthetic valves demonstrate less reverse remodeling after CRT, which manifests as shorter transplant- and VAD-free 
survival. 
Any Prosthetic Valve
(V; n=39)
No Prosthetic Valve
(NV; n=335)
P-value
Age (years) 61 ± 14 63 ± 13 0.4
Male 28 (72%) 203 (61%) 0.2
Atrial fibrillation (paroxysmal/permanent)
26 (67%)
11/ 15 (28%/ 39%)
129 (39%)
79/ 48 (24%/ 15%)
0.001
0.6/<0.001
Diabetes 9 (23%) 102 (30%) 0.3
NYHA Class IV 2 (5%) 20 (6%) 0.9
QRS duration (ms) 177 ± 33 173 ± 31 0.4
RBBB at baseline 1 (3%) 22 (7%) 0.3
Glomerular filtration rate (mL/min) 68 ± 24 66 ± 24 0.6
Cardiomyopathy duration (mos) 57 ± 45 66 ± 66 0.5
ACE-I or ARB 35 (90%) 288 (86%) 0.6
-blocker 24 (62%) 281 (84%) 0.001
Aldosterone antagonist 12 (31%) 86 (26%) 0.5
LVEF Pre-CRT (%) 19.6 ± 7.8 21.9 ± 7.2 0.07
LVESD Pre-CRT (cm) 5.5 ± 1.1 5.4 ± 1.1 0.4
LVEDD Pre-CRT (cm) 6.4 ± 0.9 6.3 ± 1.0 0.4
Absolute LVEF change (%)
+9.7 ± 12.4
(median +5)
+12.8 ± 15.7
(median +10)
0.3
Relative LVESD change (%)
-3.0 ± 15.0
(median 0)
-12.6 ± 19.8
(median -11)
0.03
Relative LVEDD change (%)
-0.4 ± 9.4
(median 0)
-7.1 ± 14.8
(median -6.0)
0.03
